Kidney International® Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: Results of a NephCure membranous nephropathy workshop Membranous nephropathy (MN) is a leading cause of adult nephrotic syndrome, and anti-PLA2R antibodies are now recognized as key biomarkers reflecting disease activity in many patients. At a 2023 NephCure workshop, experts discussed how to...
Kidney International® Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children The 2025 KDIGO executive summary updates guidance on managing nephrotic syndrome in children, introducing a treatment algorithm and aligning definitions with international standards. It revises relapse prevention strategies, recommends against routine steroid use during infections, and emphasizes personalized...
Kidney International® A health economic evaluation of the multinational, randomized controlled CONVINCE trial: cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis Patients with kidney failure often receive either high-flux hemodialysis (HD) or high-dose hemodiafiltration (HDF). Previous research shows HDF may lower the risk of death compared to HD. This study looked at whether the potential health...
Kidney International Reports® (KIR) has published as an article-in-press the results of a survey conducted by the ISN Western Europe Regional Board on preferred scientific meeting formats— in-person, virtual, or hybrid. Explore the survey findings in KIR “Nephrology health professionals' perspectives on their preferred modality for scientific meetings, balancing affordability, sustainability and opportunities to interact...
Kidney International® Treatment of patients with IgA nephropathy: a call for a new paradigm Current treatments for IgA nephropathy (IgAN), including supportive care and corticosteroids, have limited success and significant side effects. Advances in understanding IgAN’s pathogenesis have led to new targeted therapies and a proposed dual approach: targeting IgAN-specific mechanisms (e.g., pathogenic IgA production) and managing...
Kidney International® (KI) Chronic Kidney Disease–Mineral and Bone Disorder: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference The 2023 KDIGO conference confirmed that the 2017 guidelines on managing chronic kidney disease–mineral and bone disorder (CKD-MBD) remain valid but proposed reframing CKD-MBD around two clinical syndromes: CKD-associated osteoporosis and CKD-associated cardiovascular disease. Future guidelines may...
Kidney International® (KI) Are Your Kidneys OK? Detect Early to Protect Kidney Health The World Kidney Day (WKD) editorial in Kidney International highlights the importance of early kidney disease detection to protect kidney health, slow progression, and reduce cardiovascular risk. Simple tests — serum creatinine and urine albumin — enable early diagnosis, but barriers like funding...
Insights from the BKEVER trial comparing everolimus versus mycophenolate mofetil for BK polyomavirus infection in kidney transplant recipients The BKEVER trial compared everolimus (EVR) with mycophenolate mofetil (MMF) in kidney transplant recipients with BK polyomavirus (BKPyV) infection to assess which strategy led to faster viral clearance. Results showed that reducing MMF was more effective, with 81.3%...
Kidney International® KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Executive Summary The KDIGO 2025 Clinical Practice Guideline for ADPKD is the first global guideline on the evaluation, management, and treatment of this genetic disorder, focusing on areas such as diagnosis, kidney manifestations, disease progression, and extrarenal...
The ISN-KI/KIR Editorial Fellows Session: The Best of 2024/25 Articles will take place at WCN’25 on Saturday, February 8, 2025, from 9:45-11:15 a.m. KI-ISN Early-Career Researcher Awardees and ISN-KI Editorial Fellows will be honored during this session. KI-ISN Early-Career Researcher Awards honor exceptional basic and clinical science research published in Kidney International® (KI) in the...
The accepted abstracts for the ISN World Congress of Nephrology (WCN) 2025 are now published in the latest supplement to Kidney International Reports®. Read the abstracts here WCN’25 registration is possible on-site from February 5 – find out more here.
Kidney International® Evaluating the Risk of Cardiovascular Events Associated With Different Immunosuppression Treatments for Glomerular Diseases This study analyzed 1,912 adults with glomerular disease from Canada to evaluate the cardiovascular risks associated with immune therapies used for treatment. The findings reveal that prolonged exposure to calcineurin inhibitors and cyclophosphamide is linked to a higher risk of...
Kidney International® A Sub-study of the POISE-3 Randomized Trial Examined Effects of a Perioperative Hypotension-avoidance Strategy Versus a Hypertension-avoidance Strategy on the Risk of Acute Kidney Injury This sub-study of the POISE-3 trial investigated whether a strategy to prevent low blood pressure during surgery could reduce the risk of acute kidney injury (AKI). Researchers randomized 7,307 patients...
As we step into 2025, we reflect on the impactful ISN-led research of 2024. These studies deepen our understanding of kidney health and advance global kidney care as a health priority. Below, we highlight some of the year’s key contributions: An Update on the Global Disparities in Kidney Disease Burden and Care Across World Countries...
Kidney International® Outcomes From the International Society of Nephrology Hemolytic Uraemic Syndromes International Forum The 2023 ISN aHUS Forum brought together global experts to discuss key challenges in managing complement-mediated hemolytic uraemic syndromes (HUS), including nomenclature, biomarkers, and treatment protocols. Key areas for future research were identified, such as genetic predisposition, optimal complement inhibitor use, and improving...
Two significant research studies were accepted as late-breaking clinical trials at Kidney Week 2024 and have subsequently been published in Kidney International®. Higher Intraoperative Blood Pressure Does Not Reduce Acute Kidney Injury in Non-Cardiac Surgery: What Do the Results of the POISE-3 Trial Tell Us? The POISE-3 trial's analysis found no benefit in targeting a...
Kidney International® A Randomized, Open-label Clinical Trial Examined the Effects of Canagliflozin on Albuminuria and eGFR Decline Using An Individual Pre-Intervention eGFR Slope The CANPIONE study showed that canagliflozin significantly reduced albuminuria by 30.8% and slowed eGFR decline in patients with type 2 diabetes and microalbuminuria. Using a novel design comparing eGFR slopes before and during treatment,...
Kidney International® Patients With Crush Syndrome and Kidney Disease: Lessons Learned From the Earthquake in Kahramanmaraş, Türkiye This study assessed in-hospital outcomes and related factors in 1,024 adult patients diagnosed with post-earthquake crush syndrome following the 2023 earthquakes in Kahramanmaraş, Türkiye. A 9.8% mortality rate was reported. Nonsurvivors were older, were more likely to have preexisting chronic...
Calling all early-career researchers! Have you published original research in Kidney International® in 2024? Apply now for the KI-ISN Early-Career Researcher Awards and be recognized at the World Congress of Nephrology 2025. This is your chance to showcase your work and receive $500! Who can apply? First authors of original research papers (clinical or basic/translational science) Early-career...
Kidney International® Pre-transplant Anti-nephrin Antibodies are Specific Predictors of Recurrent Diffuse Podocytopathy in the Kidney Allograft This study finds that pre-transplant anti-nephrin antibodies are strongly associated with diffuse podocytopathy recurrence after kidney transplantation. Patients with these antibodies were more likely to experience disease recurrence, while those without them were less likely. The findings suggest that testing for...
